Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:brand |
Balversa
|
| gptkbp:CASNumber |
1346242-81-6
|
| gptkbp:chemicalFormula |
C25H30N6O2
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
erdafitinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
446.55 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
eye fatigue dry mouth hyperphosphatemia stomatitis nail disorder |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR4 gptkb:FGFR2 |
| gptkbp:usedFor |
gptkb:urothelial_carcinoma
gptkb:cancer |
| gptkbp:bfsParent |
gptkb:FGFR1
|
| gptkbp:bfsLayer |
6
|